Fig. 2From: Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 studySummary of plasma EBV-DNA levels over time. Median plasma EBV-DNA loads (kIU/L) over time are shown for responders and nonresponders in the pharmacodynamic analysis population. Responses were based on central review. Nonevaluable patients were considered nonresponders. C, Cycle; D, Day; EBV, Epstein–Barr virus; EOT, end of treatmentBack to article page